Modulating biomarkers such as SPP to increase tumor immunity and improve the efficacy of cancer immunotherapy
AssigneeDana-Farber Cancer Institute, Inc.
InventorsWilliam N. Haining, Adrienne Long, Robert Manguso
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to methods of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of an agent that modulates one or more biomarkers, such as inhibits one or more biomarkers listed in Table 1 and/or increases one or more biomarkers listed in Table 4, in combination with an immunotherapy.
Claims20
A method of treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of a nucleic acid agent that inhibits the copy number or the expression level of signal peptide peptidase (SPP) in combination with an immunotherapy, wherein the immunotherapy inhibits an immune checkpoint.
A method of killing cancer cells comprising contacting the cancer cell with qanila nucleic acid agent that inhibits the copy number or the expression level of SPP in combination with contacting immune cells with an immunotherapy, wherein the immunotherapy inhibits an immune checkpoint and the immune cells are i) selected from the group consisting of NK cells and T cells and ii) located in the presence of the cancer cells.
Dependencies are inferred from the claim text.